Immunotherapy duo takes on Hard-to-Treat brain tumors

NCT ID NCT02648997

Ongoing Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times

Summary

This phase 2 trial tests two immunotherapy drugs, nivolumab and ipilimumab, in 40 adults with progressive or recurrent meningioma. One group receives nivolumab alone; the other gets both drugs after radiation therapy. The goal is to see if these treatments can stop tumor growth for at least six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: nivolumab and ipilimumab (immunotherapy drugs)
What this could lead to: If successful, this could offer a new treatment option for people with recurrent meningioma that has stopped responding to standard therapies.
What could go wrong: This is a small, early-phase trial with only 40 participants. The drugs may not control tumor growth, and side effects from immunotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates